Description:
As an in vitro diagnostics (IVD) market, China ranks just behind the large, developed economies of the United States, Western Europe, and Japan. The Chinese healthcare system faces challenges similar to those in less developed countries, alongside burdens common in affluent countries such as diabetes, cardiovascular disease, and aging-related diseases. China’s potential as an IVD market is significant, standing alongside other populous countries with strong economic growth over the past decade, such as Brazil, Russia, and India (collectively with China referred to as the BRIC nations).
Scope
The Kalorama Information report, In Vitro Diagnostics (IVD) Market in China, 4th Edition, offers a comprehensive overview of the Chinese laboratory market and its key drivers. The focus is on the IVD sector, including reagents, consumables, calibrators, and controls across the following sub-segments:
- Clinical Chemistry: Routine lab testing; substrates, enzymes, homogeneous immunoassays, proteins, ISE (non-POC), HBA1c (non-POC), including urinalysis and blood chemistry testing.
- Immunoassays: Hormones and thyroid function, tumor markers, allergy, anemia, neonatal tests, prenatal tests, interleukins, PCT, toxicology, and common infectious diseases (HIV, hepatitis, influenza).
- Microbiology and Molecular Testing: Manual and automated tests, culture media (prepared or ready to use), latex tests, transport media, blood culture, sensitivity discs, Gram and other stains, MTB culture, Mycoplasma, Ureaplasma, nucleic acid testing.
- Point-of-Care Testing: All POC tests for cardiology, toxicology, coagulation, diabetes, infectious diseases, including POC and non-POC blood gas and electrolytes, and glucose self-monitoring tests.
- Histology/Cytology: PAP, HE, IHC, ISH, FISH, primary and secondary antibodies.
The report includes industry trends and country-level data such as disease incidence, life expectancy, population demographics, economic status, healthcare utilization, and other market influences.
Market Data
All market data relates to the IVD market in China at the manufacturers’ level. Data is presented for the year 2021, with forecast data extending to 2026. Compound annual growth rates (CAGRs) are provided for the 2021-2026 period.
Explore the growth potential and dynamics of the Chinese IVD market with this detailed report, designed to offer valuable insights for market participants and stakeholders.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Per Capita IVD Expenditures, by China Province/Region, 2021 ($ millions)
| Chinese Province/Region | Per Capita IVD Expenditures $ | Estimated IVD Market Size (millions USD) |
| Guangdon | $XX | $XX Million |
| Shangdon | $XX | $XX Million |
| Henan | $XX | $XX Million |
| Jiangsu | $XX | $XX Million |
| Sichuan | $XX | $XX Million |
| Hebei | $XX | $XX Million |
| Hunan | $XX | $XX Million |
| Zhejiang | $XX | $XX Million |
| Hubei | $XX | $XX Million |
| Anhui | $XX | $XX Million |
Source: Kalorama Information
